Ex-Pfizer employee convicted of insider trading on COVID drug trial
Millions of Paxlovid doses are headed for the bin in Europe
Pfizer will charge $1,390 for a five-day course of Paxlovid on the commercial market, increasing the price from the pandemic-era rate it had been giving to the US government.
Oct 13 (Reuters) - Pfizer (PFE.N) on Friday slashed its full-year revenue forecast by 13% and said it will cut $3.5 billion worth of jobs and expenses due to lower-than-expected sales of its COVID-19 vaccine and treatment.
Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022. A morning and an evening does consists of one white 100-milligram tablet of Ritonavir and two pink 150-milligram tablets of PF-07321332. REUTERS/Wolfgang Rattay/Illustration/File Photo Acquire Licensing Rights
July 31 (Reuters) - The U.S. National Institutes of Health (NIH) said on Monday that it had launched mid-stage clinical trials to test at least four treatments, including Pfizer's (PFE.N) Paxlovid, in patients with symptoms of long COVID.
(nirmatrelvir tablets and ritonavir tablets) will be available on the Pharmaceutical Benefits Scheme (PBS) to people between 50–59 years with mild to moderate COVID-19, with one additional risk factor from 1 July 2023.
A former statistician at Pfizer and his associate have been charged (PDF) with insider trading, using advance information on a drug trial to make more than $350,000 from stock purchases they executed one day before the company announced trial results for COVID-19 drug Paxlovid.
The Justice Department charged a former Pfizer employee and his friend with illegally trading shares based on non-public trial results on the Covid antiviral pill Paxlovid.
Pfizer`s Paxlovid (nirmatrelvir, ritonavir) Approved In Europe